Experimental in vivo and in vitro Models of Multiple Sclerosis: EAE and beyond

Autor: Daphne Y.S. Vogel, Fabiola Puentes, David Baker, Markus Kipp, Sandra Amor, Baukje J. van der Star, Paul van der Valk
Přispěvatelé: Pathology, Molecular cell biology and Immunology, NCA - Multiple Sclerosis and Other Neuroinflammatory Diseases
Rok vydání: 2012
Předmět:
Zdroj: Multiple Sclerosis and Related Disorders, 1(1), 15-28. Elsevier
Kipp, M, van der Star, B J, Vogel, D Y S, Puentes, F, van der Valk, P, Bakker, D & Amor, S 2012, ' Experimental in vivo and in vitro Models of Multiple Sclerosis: EAE and beyond ', Multiple Sclerosis and Related Disorders, vol. 1, no. 1, pp. 15-28 . https://doi.org/10.1016/j.msard.2011.09.002
ISSN: 2211-0348
Popis: Although the primary cause of multiple sclerosis (MS) is unknown, the widely accepted view is that aberrant (auto)immune responses possibly arising following infection(s) are responsible for the destructive inflammatory demyelination and neurodegeneration in the central nervous system (CNS). This notion, and the limited access of human brain tissue early in the course of MS, has led to the development of autoimmune, viral and toxin-induced demyelination animal models as well as the development of human CNS cell and organotypic brain slice cultures in an attempt to understand events in MS. The autoimmune models, collectively known as experimental autoimmune encephalomyelitis (EAE), and viral models have shaped ideas of how environmental factors may trigger inflammation, demyelination and neurodegeneration in the CNS. Understandably, these models have also heavily influenced the development of therapies targeting the inflammatory aspect of MS. Demyelination and remyelination in the absence of overt inflammation are better studied in toxin-induced demyelination models using cuprizone and lysolecithin. The paradigm shift of MS as an autoimmune disease of myelin to a neurodegenerative disease has required more appropriate models reflecting the axonal and neuronal damage. Thus, secondary progressive EAE and spastic models have been crucial to develop neuroprotective approaches. In this review the current in vivo and in vitro experimental models to examine pathological mechanisms involved in inflammation, demyelination and neuronal degeneration, as well as remyelination and repair in MS are discussed. Since this knowledge is the basis for the development of new therapeutic approaches for MS, we particularly address whether the currently available models truly reflect the human disease, and discuss perspectives to further optimise and develop more suitable experimental models to study MS.
Databáze: OpenAIRE
Externí odkaz: